Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Lululemon (LULU) , which belongs to the Zacks Textile - Apparel industry.This athletic apparel maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 12.91%.For the most recent quarter, Lululemon was expected to post earnings of $2.22 per share, but it ...

Investors might want to bet on Oil States International (OIS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts a ...

Key Takeaways MARA is set to report Q4 2025 results on Feb. 26, after the bell.Zacks Consensus Estimate projects a $0.23 loss per share versus $1.24 earnings last year.Revenues are estimated at $224M, up 4.4% year over year.MARA Holdings, Inc. (MARA) is set to report fourth-quarter 2025 results on Feb. 26, after the bell.The Zacks Consensus Estimate for the bottom line is pegged at a loss of 23 cents per share compared with earnings of $1.24 in the year-ago quarter.MARA’s earnings have surpassed the Zacks C ...

TXO Partners LP (TXO) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

AeroVironment (AVAV) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended January 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ...

The market expects Esperion Therapeutics (ESPR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other ha ...

Wall Street expects a year-over-year increase in earnings on higher revenues when NeuroPace, Inc. (NPCE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on March ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Evolus, Inc. (EOLS) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on March 3. ...

Key Takeaways The Zacks Consensus Estimate pegs CPNG's Q4 earnings at 2 cents per share, down 50% year over year.Coupang's developing offerings segment is expected to remain a drag on profitability in Q4.Coupang's elevated effective tax rate is expected to limit bottom-line conversion in the quarter.Coupang (CPNG) is scheduled to report its fourth-quarter 2025 results on Feb. 26.The Zacks Consensus Estimate for CPNG’s fourth-quarter 2025 revenues is currently pegged at $9.14 billion, indicating a 14.78% inc ...